Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBITDA: 2020-2024

Historic EBITDA for iSpecimen (ISPC) over the last 5 years, with Dec 2024 value amounting to -$12.5 million.

  • iSpecimen's EBITDA fell 93.12% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year decrease of 23.71%. This contributed to the annual value of -$12.5 million for FY2024, which is 12.61% down from last year.
  • Latest data reveals that iSpecimen reported EBITDA of -$12.5 million as of FY2024, which was down 12.61% from -$11.1 million recorded in FY2023.
  • iSpecimen's 5-year EBITDA high stood at -$2.4 million for FY2020, and its period low was -$12.5 million during FY2024.
  • For the 3-year period, iSpecimen's EBITDA averaged around -$11.3 million, with its median value being -$11.1 million (2023).
  • Data for iSpecimen's EBITDA shows a maximum YoY crashed of 146.23% (in 2021) over the last 5 years.
  • Over the past 5 years, iSpecimen's EBITDA (Yearly) stood at -$2.4 million in 2020, then slumped by 146.23% to -$5.9 million in 2021, then slumped by 72.92% to -$10.2 million in 2022, then fell by 8.32% to -$11.1 million in 2023, then decreased by 12.61% to -$12.5 million in 2024.